Surfactant Protein-D Therapy for COPD Lung Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic obstructive pulmonary disease (COPD) are ineffective in addressing the progressive deterioration of lung function and mortality associated with the disease.
Innovation Solution
Administration of surfactant protein-D (SP-D), either native or recombinant, to treat COPD, which helps in regulating lipid metabolism and reducing airway inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic approaches are used for COPD, then treatment is provided, but they are ineffective against progressive deterioration of lung function and mortality
Solution Approach 1:
The patent introduces surfactant protein-D (SP-D) as a mediator substance that regulates lipid metabolism in alveolar macrophages. SP-D acts as an intermediary that prevents the formation of lipid-laden foamy macrophages, thereby protecting against airway inflammation and emphysematous changes. This intermediary substance addresses the ineffectiveness of existing therapies by targeting the underlying lipid metabolism dysfunction.
2Ease of operation
If inhaled oxidants such as cigarette smoke are present, then respiratory activity is maintained, but proteolytic enzymes and ROS are dysregulated causing inflammatory mediators and metalloproteases release
Solution Approach 1:
The patent applies preliminary anti-action by administering SP-D before the harmful effects of inhaled oxidants fully manifest. SP-D pre-regulates lipid metabolism in macrophages, preventing the subsequent dysregulation of proteolytic enzymes and reactive oxygen species. This preventive approach counteracts the harmful effects before they cause significant inflammation and tissue damage.
3Power
If alveolar macrophages release metalloproteases, then proteolytic activity increases, but alveolar structure is damaged
Solution Approach 1:
SP-D serves as a protective intermediary between proteolytic activity and alveolar structure. By regulating lipid metabolism in macrophages, SP-D modulates the release of metalloproteases, allowing necessary proteolytic function while preventing excessive activity that would damage alveolar structures. This intermediary regulation maintains the balance between proteolytic power and structural integrity.
Data Source
AI summary
The present invention provides a new therapy of chronic obstructive pulmonary disease (COPD) using surfactant protein-D (SP-D) or its fragment.